TopoTarget USA, Inc.

TopoTarget is a dynamic international biotech company dedicated to finding "Answers for cancer".

Founded by clinicians with a thorough knowledge of the molecular mechanisms of cancer, our goal is to find and develop cancer therapies, bringing them to the market to benefit patients. As well as a strong clinical development team, we have top class experts in our preclinical and regulatory departments. Currently, we have a late stage pipeline with 9 products in clinical development and a broad range of preclinical candidates. Using our own highly specialised dedicated sales team, we launched our first product, Savene® in Europe in 2006, and in the US in 2007 under the brand name Totect™.

Savene®/Totect™ is used for the treatment of anthracycline extravasation, an accident that can occur during chemotherapy. Our lead product in clinical development, belinostat, has shown proof-of-concept and is expected to enter pivotal trials during 2008. Belinostat has a novel mechanism of action and is being developed for a number of cancer indications for both haematological malignancies and solid tumors.

As well as developing products from its own research and development efforts, TopoTarget continually looks for opportunities to strengthen its portfolio of products via acquisitions or in-licensing and also pursues a strategy of out-licensing when appropriate to create value for company stakeholders. Most recently, TopoTarget added two cancer products in clinical development to its pipeline following the acquisition in June 2007 of a Swiss company, now TopoTarget Switzerland SA. TopoTarget is headquartered in Denmark and has streamlined operations in the US, Switzerland, Germany and the UK with approximately 120 employees globally. The company is listed on the OMX Nordic Exchange in Copenhagen under the symbol (OMX: TOPO).